| Drug ID: | Drug26 |
|---|---|
| Drug Name: | Mesalazine |
| CID: | 4075 |
| DrugBank ID: | DB00244 |
| Modality: | Small Molecule |
| Groups: | approved |
| US Approved: | YES |
| Other Approved: | YES |
| Identifier: | NCT05992142, , NCT01532648, , NCT02665845, , NCT00603733, , NCT02683759, , NCT03804931, , NCT01320436, , NCT00984568, , NCT00167882, , NCT00713310, , NCT01004185, , NCT01903252, , NCT00151892, , NCT00349388, , NCT05753267, , NCT05781698, , NCT05988528, , NCT05567068, , NCT05986136, , NCT05119 |
| Molecular Formula: | C7H7NO3 |
| Molecular Weight: | 153.14 g/mol |
| Isomeric SMILES: | C1=CC(=C(C=C1N)C(=O)O)O |
| Synonyms: | 5-Aminosalicylic acid; mesalamine; Mesalazine; 89-57-6; 5-Amino-2-hydroxybenzoic acid; 5-ASA; m-Aminosalicylic acid; Lialda; Fisalamine; Apriso |
| Phase 0: | 1 |
| Phase 1: | 39 |
| Phase 2: | 43 |
| Phase 3: | 94 |
| Phase 4: | 27 |
| Description: | An anti-inflammatory agent, structurally related to the salicylates, which is active in inflammatory bowel disease. It is considered to be the active moiety of sulphasalazine. (From Martindale, The Extra Pharmacopoeia, 30th ed) |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| dt238 | 4075 | Mesalamine | 3028 | HSD17B10 | Homo sapiens (human) | None | |
| dt239 | 4075 | Mesalamine | 2744 | GLS | Homo sapiens (human) | None | |
| dt240 | 4075 | Mesalamine | 3586 | IL10 | Homo sapiens (human) | None | |
| dt241 | 4075 | Mesalamine | 5743 | PTGS2 | Homo sapiens (human) | Inhibitor | |
| dt242 | 4075 | Mesalamine | 5742 | PTGS1 | Homo sapiens (human) | Inhibitor | |
| dt243 | 4075 | Mesalamine | 240 | ALOX5 | Homo sapiens (human) | Inhibitor | |
| dt244 | 4075 | Mesalamine | 5468 | PPARG | Homo sapiens (human) | Agonist | |
| dt245 | 4075 | Mesalamine | 1147 | CHUK | Homo sapiens (human) | Inhibitor | |
| dt246 | 4075 | Mesalamine | 3551 | IKBKB | Homo sapiens (human) | Inhibitor | |
| dt247 | 4075 | Mesalamine | 4843 | NOS2 | Homo sapiens (human) | 17503181 | Inhibitor |
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| NCT05538026 | Effectiveness of Fecal Microbiota Transplantation as add-on Therapy in Mild-to-moderate Ulcerative Colitis | NA | COMPLETED | Bogomolets National Medical University | Ulcerative Colitis Chronic Mild|Inflammatory Bowe… | DRUG: Mesalazine|BIOLOGICAL: Fecal transplantation | Details |
| NCT05386290 | A Multicentered Prospective Cohort Study of Chinese IBD Patients | NULL | UNKNOWN | Peking Union Medical College Hospital | Ulcerative Colitis|Crohn Disease | DRUG: Infliximab|DRUG: Vedolizumab|DRUG: Ustekinu… | Details |
| NCT05205603 | Efficacy of Mesalazine Combined With Biologics in the Treatment of Moderate to Severe Ulcerative Colitis | PHASE4 | UNKNOWN | Sixth Affiliated Hospital, Sun Yat-sen University | Ulcerative Colitis|Efficacy, Self|Biologics|Mesal… | DRUG: Infliximab|DRUG: Vedolizumab|DRUG: Mesalazi… | Details |
| NCT04276649 | A Retrospective Analysis: the Influence of Caltrate Supplement on the Effect of Mesalazine in Ulcerative Colitis | NULL | COMPLETED | Second Affiliated Hospital of Wenzhou Medical University | Ulcerative Colitis|Vitamin D Deficiency|Vitamin D… | DRUG: Caltrate | Details |
| NCT04133194 | Adherence of a 1.600 mg Single Tablet 5-ASA Treatment of Ulcerative Colitis | PHASE4 | UNKNOWN | Flemming Bendtsen | Ulcerative Colitis | DRUG: Mesalazine|DRUG: Mesalazine | Details |
| NCT03917095 | The Safety and Efficacy of TET Enema in the Treatment of UC | NA | UNKNOWN | The Second Hospital of Nanjing Medical University | Ulcerative Colitis Chronic Mild|Ulcerative Coliti… | DEVICE: The Colonic Transendoscopic enteral Tubin… | Details |
| NCT03441893 | Role of Intestinal Protozoa and Helminths in the Course of Ulcerative Colitis | PHASE1|PHASE2 | UNKNOWN | Research Institute of Epidemiology, Microbiology and Infectious Diseases, Uzbekistan | Ulcerative Colitis|Ulcerative Colitis Exacerbatio… | DIAGNOSTIC_TEST: parasitological diagnostics (cop… | Details |
| NCT03412682 | To Evaluate the Efficacy and Safety of FE 999315 in Japanese Subjects With Mild to Moderate Active Ulcerative Colitis | PHASE3 | COMPLETED | Ferring Pharmaceuticals | Colitis, Ulcerative | DRUG: Budesonide (6 mg)|DRUG: Budesonide (9 mg)|D… | Details |
| NCT03110198 | Mesalazine With Hydrocortisone Sodium Succinate Enema for 4-Week Treatment in Patients With Ulcerative Colitis | PHASE4 | UNKNOWN | Xijing Hospital of Digestive Diseases | Ulcerative Colitis, Unspecified | DRUG: Mesalazine|DRUG: hydrocortisone sodium succ… | Details |
| NCT03104036 | Faecal Bacteriotherapy for Ulcerative Colitis | PHASE2 | COMPLETED | Institute for Clinical and Experimental Medicine | Ulcerative Colitis | OTHER: Faecal bacterial transplantation|DRUG: Mes… | Details |
| NCT02769494 | The Efficacy of Topical Mesalazine Sustained-Release Tablets in Crohn's Disease Patients With Oral Ulcer | PHASE3 | WITHDRAWN | Xijing Hospital of Digestive Diseases | Crohn's Disease|Oral Ulcer | DRUG: Mesalazine Sustained-Release Tablets|DRUG: … | Details |
| NCT02537210 | Aminosalicylic Acid Withdrawal Study in Long Standing Inactive Ulcerative Colitis | NA | COMPLETED | Chinese University of Hong Kong | Colitis, Ulcerative|Aminosalicylic Acid | DRUG: Mesalazine|DRUG: Placebo oral capsule | Details |
| NCT02368717 | An Efficacy and Safety Study of PENTASA in Chinese Patients With Left-sided Active Ulcerative Colitis Followed by a 24-Week Open-Label Extension Phase | PHASE3 | COMPLETED | Ferring Pharmaceuticals | Ulcerative Colitis | DRUG: Mesalazine Enema|DRUG: Placebo Enema | Details |
| NCT02335281 | Standardized Fecal Microbiota Transplantation for Inflammatory Bowel Disease | PHASE2 | UNKNOWN | Yanling Wei | Inflammatory Bowel Disease|Ulcerative Colitis|Cro… | PROCEDURE: FMT|DRUG: Mesalazine | Details |
| NCT02261636 | Induction and Maintenance of Remission With Pentasa as Ulcerative Colitis Treatment | NULL | COMPLETED | Ferring Pharmaceuticals | Ulcerative Colitis | DRUG: mesalazine | Details |
| NCT02190526 | Effects of Mesalamine and Amitriptyline on Irritable Bowel Syndrome | PHASE4 | WITHDRAWN | Tehran University of Medical Sciences | Diarrhea- Predominant Irritable Bowel Syndrome|Qu… | DRUG: Mesalazine(asacol 800 mg)|DRUG: Amitriptyli… | Details |
| NCT02093663 | Safety and Efficacy of MMX Mesalamine/Mesalazine in Pediatric Subjects With Mild to Moderate Ulcerative Colitis | PHASE3 | COMPLETED | Shire | Ulcerative Colitis | DRUG: MMX Mesalamine/Mesalazine (Low Dose)|DRUG: … | Details |
| NCT02044952 | Efficacy and Safety Study of Tripterygium Glycoside in the Treatment of Crohn's Disease for Induction Remission | PHASE2|PHASE3 | UNKNOWN | Zhu Weiming | Inflammatory Bowel Diseases|Crohn's Disease|Gastr… | DRUG: Mesalazine, Tripterygium glycosides | Details |
| NCT01745770 | TID 1000 mg Mesalazine Versus TID 2x500 mg Mesalazine in Active Ulcerative Colitis (UC) | PHASE3 | COMPLETED | Dr. Falk Pharma GmbH | Active Ulcerative Colitis | DRUG: Mesalazine - TID 1000 mg|DRUG: Mesalazine -… | Details |
| NCT01699438 | Mesalazine Treatment in IBS (The MIBS Study) | PHASE2 | COMPLETED | Hans Törnblom | Irritable Bowel Syndrome | DRUG: Mesalazine|DRUG: Placebo | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| No data available | ||||||
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| S01 | Anti-inflammatory | inflammatory | 5-Aminosalicylates (5-ASAs); corticosteroids | Crohn's disease and ulcerative colitis are the two main com… | Details |
Twelve-month persistency with oral 5-aminosalicylic acid therapy for ulcerative…
PMID: 21879279
Year: 2011
Relationship Type:
Treatment
Score: 5.1
BACKGROUND: Patients receiving 5-aminosalicylic acid (5-ASA) require long-term therapy to achieve good outcomes. Persistency (duration of time from i…
Expanding applications: the potential usage of 5-aminosalicylic acid in diverti…
PMID: 21567193
Year: 2011
Relationship Type:
Treatment
Score: 5.1
Diverticular disease is a common bowel condition, the pathogenesis of which is incompletely understood. Acute exacerbations of diverticular disease u…
Clinical trial: once-daily mesalamine granules for maintenance of remission of …
PMID: 20937044
Year: 2010
Relationship Type:
Treatment
Score: 5.1
BACKGROUND: Ulcerative colitis (UC) is a chronic relapsing and remitting idiopathic inflammatory bowel disorder. AIM: To evaluate once-daily mesalami…
Showing 181-183 of 183 articles